Raptor Pharmaceutical Corp. to Present at the Stifel Nicolaus Healthcare Conference 2012
Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. to Present at the Stifel Nicolaus Healthcare
NOVATO, Calif., 2012-08-30 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical
Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that
Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an
overview of the Company at the Stifel Nicolaus Healthcare Conference in Boston,
MA at the Four Seasons Hotel. Raptor's presentation will take place on
Thursday, September 6, 2012 beginning at 1:30 p.m. ET.
A live audio webcast and 14-day archive of the Stifel Nicolaus presentation
will be available at http://ir.raptorpharma.com/events.cfm
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development to
potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis
("NASH"), Huntington's disease ("HD"), aldehyde dehydrogenase deficiency
("ALDH2"), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
CONTACT: Trout Group (investors)
EVC Group (media)